AIRLINK 153.32 Decreased By ▼ -2.80 (-1.79%)
BOP 9.79 Decreased By ▼ -0.22 (-2.2%)
CNERGY 7.09 Increased By ▲ 0.04 (0.57%)
CPHL 81.71 Decreased By ▼ -2.42 (-2.88%)
FCCL 44.04 Decreased By ▼ -0.61 (-1.37%)
FFL 14.63 Decreased By ▼ -0.26 (-1.75%)
FLYNG 36.67 Increased By ▲ 3.33 (9.99%)
HUBC 133.47 Decreased By ▼ -2.08 (-1.53%)
HUMNL 12.85 Increased By ▲ 0.03 (0.23%)
KEL 4.38 Increased By ▲ 0.22 (5.29%)
KOSM 5.42 Increased By ▲ 0.35 (6.9%)
MLCF 70.20 Decreased By ▼ -1.40 (-1.96%)
OGDC 202.93 Increased By ▲ 2.71 (1.35%)
PACE 5.09 Increased By ▲ 0.04 (0.79%)
PAEL 43.10 Decreased By ▼ -0.79 (-1.8%)
PIAHCLA 16.47 Decreased By ▼ -0.27 (-1.61%)
PIBTL 8.82 Increased By ▲ 0.11 (1.26%)
POWER 14.40 Decreased By ▼ -0.51 (-3.42%)
PPL 151.80 Increased By ▲ 3.32 (2.24%)
PRL 29.52 Decreased By ▼ -0.03 (-0.1%)
PTC 20.39 Decreased By ▼ -0.46 (-2.21%)
SEARL 81.51 Decreased By ▼ -1.96 (-2.35%)
SSGC 36.08 Decreased By ▼ -3.95 (-9.87%)
SYM 14.58 Decreased By ▼ -0.30 (-2.02%)
TELE 7.01 Increased By ▲ 0.02 (0.29%)
TPLP 8.32 Decreased By ▼ -0.06 (-0.72%)
TRG 64.08 Increased By ▲ 0.45 (0.71%)
WAVESAPP 9.64 Increased By ▲ 0.77 (8.68%)
WTL 1.33 Decreased By ▼ -0.01 (-0.75%)
YOUW 3.65 Increased By ▲ 0.19 (5.49%)
AIRLINK 153.32 Decreased By ▼ -2.80 (-1.79%)
BOP 9.79 Decreased By ▼ -0.22 (-2.2%)
CNERGY 7.09 Increased By ▲ 0.04 (0.57%)
CPHL 81.71 Decreased By ▼ -2.42 (-2.88%)
FCCL 44.04 Decreased By ▼ -0.61 (-1.37%)
FFL 14.63 Decreased By ▼ -0.26 (-1.75%)
FLYNG 36.67 Increased By ▲ 3.33 (9.99%)
HUBC 133.47 Decreased By ▼ -2.08 (-1.53%)
HUMNL 12.85 Increased By ▲ 0.03 (0.23%)
KEL 4.38 Increased By ▲ 0.22 (5.29%)
KOSM 5.42 Increased By ▲ 0.35 (6.9%)
MLCF 70.20 Decreased By ▼ -1.40 (-1.96%)
OGDC 202.93 Increased By ▲ 2.71 (1.35%)
PACE 5.09 Increased By ▲ 0.04 (0.79%)
PAEL 43.10 Decreased By ▼ -0.79 (-1.8%)
PIAHCLA 16.47 Decreased By ▼ -0.27 (-1.61%)
PIBTL 8.82 Increased By ▲ 0.11 (1.26%)
POWER 14.40 Decreased By ▼ -0.51 (-3.42%)
PPL 151.80 Increased By ▲ 3.32 (2.24%)
PRL 29.52 Decreased By ▼ -0.03 (-0.1%)
PTC 20.39 Decreased By ▼ -0.46 (-2.21%)
SEARL 81.51 Decreased By ▼ -1.96 (-2.35%)
SSGC 36.08 Decreased By ▼ -3.95 (-9.87%)
SYM 14.58 Decreased By ▼ -0.30 (-2.02%)
TELE 7.01 Increased By ▲ 0.02 (0.29%)
TPLP 8.32 Decreased By ▼ -0.06 (-0.72%)
TRG 64.08 Increased By ▲ 0.45 (0.71%)
WAVESAPP 9.64 Increased By ▲ 0.77 (8.68%)
WTL 1.33 Decreased By ▼ -0.01 (-0.75%)
YOUW 3.65 Increased By ▲ 0.19 (5.49%)
BR100 12,110 Decreased By -38.6 (-0.32%)
BR30 35,339 Decreased By -55.1 (-0.16%)
KSE100 113,569 Decreased By -533.7 (-0.47%)
KSE30 34,681 Decreased By -127.9 (-0.37%)
Business & Finance

Pharma firms to resume production of paracetamol after meeting with Dar: Ministry of Finance

  • Dar met heads of major pharmaceutical companies to discuss revised retail price of paracetamol products
Published October 26, 2022

The pharmaceutical industry has come to an agreement with the government over revised prices of paracetamol products, and also initiated production of the medicine, according to an official statement by the finance ministry on Wednesday.

The development comes after Federal Minister for Finance and Revenue Ishaq Dar held a meeting with heads of major pharmaceutical companies to discuss the retail price of paracetamol products, said the Ministry of Finance.

“The pharma industry agreed upon the reduced prices of paracetamol 500mg tablet at Rs2.35, paracetamol extra 500 mg at Rs2.75 and syrup at Rs117.6, which is almost half the price increase demanded by them,” read the statement.

Moreover, the production of paracetamol products has been initiated, added the statement.

The development comes days after GlaxoSmithKline Consumer Healthcare (GSKCH) declared force majeure regarding the production of Panadol Tablets (or generic paracetamol), Panadol Extra Tablets and Children’s Panadol Liquid Range.

In a filing to the Pakistan Stock Exchange (PSX) on Friday, the company had said that it sent “several letters to various government stakeholders regarding the critical issue of extraordinary and rapid increase in paracetamol (raw material) prices in Pakistan.”

But, according to media reports, the same was rejected after a prolonged delay by the latter without any intimation of reason(s) given to the company.“

The prices of medicines in Pakistan are regulated by the Drug Regulatory Authority of Pakistan (DRAP), which means pharmaceutical companies cannot increase rates unless the authority gives them a go-ahead.

Talking to Business Recorder, Dr Kaiser Waheed, former chairman of the Pakistan Pharmaceutical Manufacturers’ Association (PPMA), the representative body of pharma companies, said that the agreement was reached between the government and GSKCH, not the “entire pharma industry”.

Waheed said the pharmaceutical industry was in talks with the government to provide subsidies to the sector. “However, the government said that it cannot afford to give any subsidy,” he added.

Last month, the PPMA warned that it will increase the prices of select medicines if the DRAP does not hold talks by Monday, October 3.

Comments

Comments are closed.